Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1970 1
1974 2
1975 1
1977 3
1978 6
1979 3
1980 7
1981 4
1982 4
1983 3
1984 3
1985 5
1986 5
1987 4
1988 7
1989 4
1990 7
1991 2
1992 5
1993 3
1994 5
1995 4
1997 2
1998 3
1999 4
2000 5
2001 5
2002 4
2003 3
2004 5
2005 3
2006 4
2007 6
2008 7
2009 17
2010 8
2011 11
2012 7
2013 19
2014 22
2015 19
2016 21
2017 22
2018 27
2019 29
2020 33
2021 41
2022 25
2023 26
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

420 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Kang YK, et al. Among authors: kadowaki s. Lancet Oncol. 2022 Feb;23(2):234-247. doi: 10.1016/S1470-2045(21)00692-6. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030335 Clinical Trial.
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Kato K, et al. Among authors: kadowaki s. Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30. Lancet Oncol. 2019. PMID: 31582355 Clinical Trial.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T. Shitara K, et al. Among authors: kadowaki s. Lancet Oncol. 2019 Jun;20(6):827-836. doi: 10.1016/S1470-2045(19)30088-9. Epub 2019 Apr 29. Lancet Oncol. 2019. PMID: 31047804 Clinical Trial.
Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.
Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, Kitayama J. Ishigami H, et al. Among authors: kadowaki s. J Clin Oncol. 2018 Jul 1;36(19):1922-1929. doi: 10.1200/JCO.2018.77.8613. Epub 2018 May 10. J Clin Oncol. 2018. PMID: 29746229 Clinical Trial.
A20 Haploinsufficiency in East Asia.
Kadowaki T, Kadowaki S, Ohnishi H. Kadowaki T, et al. Among authors: kadowaki s. Front Immunol. 2021 Nov 26;12:780689. doi: 10.3389/fimmu.2021.780689. eCollection 2021. Front Immunol. 2021. PMID: 34899744 Free PMC article. Review.
Commentary: Key is reproducibility.
Honjo O, Kadowaki S. Honjo O, et al. Among authors: kadowaki s. JTCVS Tech. 2021 Jul 30;9:124-125. doi: 10.1016/j.xjtc.2021.07.017. eCollection 2021 Oct. JTCVS Tech. 2021. PMID: 34647079 Free PMC article. No abstract available.
420 results